Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07472790 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma

Name: A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma — clinical trial record (NCT07472790)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorBeijing Bio-Targeting Therapeutics Technology Co., Ltd

Started2026-07-31

View on ClinicalTrials.gov ↗

Amendment history

2026-07-13

Study Status v1

Start date2026-03-31→2026-07-31

2026-03-12

Original filing

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

3 trials monitored

See all monitored trials

Glioma

666 trials monitored

See 38 trials at risk

A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma

Trial Details

NCT Number	NCT07472790
Lead Sponsor	Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions	High-grade Glioma
Enrollment	15 participants
Start Date	2026-07-31
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-14